Open AccessExpression of urokinase‐type plasminogen activator and plasminogen activator inhibitor in colon disease
Author(s) -
Miseljic Slobodan,
Galandiuk Susan,
Myers Stephen D.,
Wittliff James L.
Publication year - 1995
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.1860090613
Subject(s) - medicine , colorectal cancer , plasminogen activator , gastroenterology , colonoscopy , ulcerative colitis , biopsy , immunohistochemistry , plasminogen activator inhibitor 1 , pathology , cancer , disease
Surveillance colonoscopy and biopsy are inaccurate methods of predicting the likelihood of ulcerative colitis patients to develop colon carcinoma. We examined uPA and PAI‐1 as potential markers for assessing these patients and those with familial polyposis who are at risk of developing colon cancer. For comparison, biopsies of normal colon and Crohn's disease were evaluated. We examined 77 colonic mucosa specimens taken from patients undergoing elective resection for benign and malignant colonic disease. uPA and PAI‐1 were measured using a monoclonal antibody‐based ELISA kit (American Diagnostica, Greenwich, CT) and expressed as ng/mg extract protein. Intra‐ and interassay controls of uPA gave CV = 3–4% and CV = 8–9%, respectively, while those for PAI‐1 were 6–7% and 10–11%, respectively. The Mann‐Whitney test showed that both uPA and PAI‐1 expression were significantly higher in colon cancer, chronic ulcerative colitis, and Crohn's disease than in normal colon. uPA in familial polyposis samples was similar to that of normal colon, while PAI‐1 was much lower than in normal colon. Neither patient age nor sex appeared to influence the expression of these potential markers in any tissue. The pattern of uPA and PAI‐1 expression in normal, benign and malignant colon suggests these proteins deserve further consideration as markers for assessing colon carcinoma risk.